MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

282644

MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials

The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials for the treatment of multiple myeloma. The financial support for the therapy’s development is being given by the MMRF through an investment made via its venture philanthropy arm, the Myeloma Investment Fund. The terms of the investment were not disclosed. “Our investment in Indapta’s G-NK cell therapy is consistent with our strategy…

You must be logged in to read/download the full post.